Fil LTD Hutchmed (China) LTD Transaction History

Fil LTD

  • $95.5 Billion
  • Q2 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$12.08 - $18.56 $454,594 - $698,449
37,632 Added 49.52%
113,625 $1.91 Million
Q4 2023

Feb 13, 2024
BUY
$16.25 - $20.23 $72,345 - $90,063
4,452 Added 6.22%
75,993 $1.38 Million
Q3 2023

Nov 13, 2023
BUY
$11.85 - $16.95 $256,516 - $366,916
21,647 Added 43.39%
71,541 $1.21 Million
Q2 2023

Aug 11, 2023
SELL
$10.78 - $17.73 $176,447 - $290,204
-16,368 Reduced 24.7%
49,894 $598,000
Q1 2023

May 11, 2023
BUY
$13.02 - $19.87 $255,738 - $390,286
19,642 Added 42.13%
66,262 $862,000
Q4 2022

Feb 13, 2023
BUY
$7.65 - $15.51 $80,937 - $164,095
10,580 Added 29.36%
46,620 $689,000
Q3 2022

Nov 10, 2022
BUY
$8.63 - $15.52 $311,025 - $559,340
36,040 New
36,040 $319,000
Q2 2022

Aug 12, 2022
SELL
$8.59 - $20.77 $82,927 - $200,513
-9,654 Closed
0 $0
Q1 2022

May 13, 2022
SELL
$15.52 - $35.65 $148,324 - $340,707
-9,557 Reduced 49.75%
9,654 $183,000
Q4 2021

Feb 14, 2022
SELL
$28.89 - $35.33 $10.5 Million - $12.8 Million
-362,438 Reduced 94.97%
19,211 $674,000
Q3 2021

Nov 15, 2021
SELL
$35.66 - $42.94 $3.62 Million - $4.35 Million
-101,406 Reduced 20.99%
381,649 $14 Million
Q2 2021

Aug 13, 2021
BUY
$23.7 - $39.27 $3.25 Million - $5.38 Million
137,068 Added 39.62%
483,055 $19 Million
Q1 2021

May 14, 2021
BUY
$27.01 - $36.8 $1.95 Million - $2.66 Million
72,230 Added 26.38%
345,987 $9.78 Million
Q4 2020

Feb 08, 2021
BUY
$27.51 - $34.36 $157,329 - $196,504
5,719 Added 2.13%
273,757 $8.77 Million
Q3 2020

Nov 13, 2020
BUY
$25.8 - $34.61 $6.92 Million - $9.28 Million
268,038 New
268,038 $8.66 Million

Others Institutions Holding HCM

# of Institutions
66
Shares Held
8.25M
Call Options Held
3.8K
Put Options Held
2.4K
View Full List

About HUTCHMED (China) Ltd

HCM Quotes by TradingView
  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Fil LTD Portfolio

Follow Fil LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fil LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email